Julia Owens PhD

Dr. Julia C. Owens co-founded Millendo Therapeutics in 2012 and has served as President and Chief Executive Officer since its inception. Dr. Owens has an extensive track record of building successful biopharmaceutical companies, with particular expertise in business development, strategic partnerships and mergers and acquisitions. Prior to co-founding Millendo, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that culminated in a major research partnership with Merck & Co. and the acquisition of a new platform discovery program for the company. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals where she established key strategic partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) where she led partnering for oncology and immunology as well as technology acquisition efforts, after beginning her biotech business career at the University of California, San Francisco Office of Technology Management.

Dr. Owens serves on the Board of Directors for the Biotechnology Innovation Organization (BIO) and its Emerging Companies Section Governing Board, the Leadership Council for the Life Sciences Institute at the University of Michigan, the Investment Advisory Board for the U-M Monroe-Brown Seed Fund and the Millendo Therapeutics Board of Directors.

Dr. Owens holds a Ph.D. in biochemistry from the University of California, San Francisco and a B.S. in chemistry and B.A. in molecular and cellular biology from the University of California, Berkeley.